1 citations
,
September 2022 in “F1000Research” Digital gangrene can be an initial symptom of late-onset systemic lupus erythematosus.
54 citations
,
January 1983 in “Archives of Dermatology” KFSD is a rare condition causing scarring hair loss, with no effective treatment known at the time of the report.
5 citations
,
November 2024 in “Journal of Clinical Immunology” Dupilumab effectively controls symptoms in infants with Netherton syndrome.
4 citations
,
May 2012 in “BMJ Case Reports” A Nigerian baby with neonatal lupus got better with treatment by 6 months.
20 citations
,
January 2005 in “Australasian Journal of Dermatology” A woman had a skin condition with increased normal elastic fibers, not related to other known disorders, likely due to aging.
1 citations
,
October 2025 in “Journal of Dermatological Treatment” Dupilumab improves eczema in Netherton Syndrome but not ichthyosis linearis circumflexa.
September 2025 in “Arthritis Research & Therapy” BMS-470539 reduces skin fibrosis and inflammation.
August 2022 in “F1000Research” Digital gangrene can be a rare first sign of late-onset systemic lupus erythematosus.
November 2012 in “The Journal for Nurse Practitioners” Systemic lupus erythematosus is a complex autoimmune disease mainly affecting women, with varied symptoms and unknown exact cause.
1 citations
,
May 2024 in “Advanced Functional Materials” The artificial skin promotes better wound healing and skin regeneration.
April 2025 in “Journal of Investigative Dermatology” Fibronectin is essential for hair follicle regeneration by supporting stem cells.
November 2018 in “Journal of dermatology & cosmetology” The document reports the first case of a rare skin condition in Colombia, the 19th case worldwide.
1 citations
,
November 2020 in “Asian Journal of Pharmaceutical and Clinical Research” Nanoparticles may improve treatment for lung disease by targeting cells better and reducing side effects.
52 citations
,
September 2021 in “Kidney International” COVID-19 vaccination may trigger lupus in some people.
36 citations
,
January 2012 in “Dermatology” Stopping gefitinib improved scalp condition in a woman with lung cancer.
October 2025 in “The Sri Lanka Journal of Dermatology” SJS and TEN can cause long-term organ damage and psychological issues beyond skin and eye problems.
13 citations
,
July 2016 in “Indian Journal of Dermatology” DPR can show different hair characteristics, as seen in two brothers with normal hair.
January 2026 in “JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH” A 62-year-old man with diabetes and kidney disease had itchy skin lesions diagnosed as perforating folliculitis, treated with medication and skin care.
12 citations
,
February 2014 in “PLoS ONE” Topical rapamycin may effectively treat fibrous papules on the face.
September 2024 in “Dermatologica Sinica” Ponatinib can cause a rare skin reaction that resolves with topical treatment and temporary drug discontinuation.
80 citations
,
January 1995 in “The Nephron journals/Nephron journals” The treatment was effective for lupus nephritis with manageable side effects.
July 2024 in “Journal of Investigative Dermatology” ATR12-351 ointment safely delivers LEKTI protein to the skin, reducing enzyme activity in Netherton syndrome.
33 citations
,
June 2009 in “Journal of Cutaneous Pathology” Erlotinib can cause nonscarring hair loss and itchy skin.
September 2014 in “Emergency Medicine News” The man's skin condition improved with sun protection and topical steroids, but UV exposure still caused flare-ups.
May 2022 in “Research Square (Research Square)” Certain Chinese herbs may help treat kidney fibrosis by targeting TGF-β.
June 2025 in “Neurology India” Anti-SRP myopathy can be linked to systemic lupus erythematosus and may improve with specific treatment.
58 citations
,
November 1969 in “British Journal of Dermatology” Netherton's disease causes multiple hair defects.
273 citations
,
May 2017 in “The Lancet” Some drugs can cause rare but potentially deadly skin reactions, and early treatment and avoiding the drug again are key.
39 citations
,
November 2015 in “Pediatric Nephrology” Rituximab leads to longer remission and fewer side effects than cyclophosphamide.
2 citations
,
January 2025 in “Journal of Nanobiotechnology” A new engineered treatment shows promise in curing heart fibrosis.